The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Patients with Acute Myeloid Leukemia
Abstract
Venetoclax-based therapy can induce responses in approximately 70% of older previously untreated patients with acute myeloid leukemia (AML). However, up-front resistance as well as relapse following initial response demonstrates the need for a deeper understanding of resistance mechanisms. In the present study, we report that responses to venetoclax +azacitidine in patients with AML correlate closely with developmental stage, where phenotypically primitive AML is sensitive, but monocytic AML is more resistant. Mechanistically, resistant monocytic AML has a distinct transcriptomic profile, loses expression of venetoclax target BCL2, and relies on MCL1 to mediate oxidative phosphorylation and survival. This differential sensitivity drives a selective process in patients which favors the outgrowth of monocytic subpopulations at relapse. Based on these findings, we conclude that resistance to venetoclax + azacitidine can arise due to biological properties intrinsic to monocytic differentiation. We propose that optimal AML therapies should be designed so as to independently target AML subclones that may arise at differing stages of pathogenesis. Significance: Identifying characteristics of patients who respond poorly to venetoclax-based therapy and devising alternative therapeutic strategies for such patients are important topics in AML. We show that venetoclax resistance can arise due to intrinsic molecular/metabolic properties of monocytic AML cells and that such properties can potentially be targeted with alternative strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bonnet, D., & Dick, J. E. (1997) · Nature Medicine · doi:10.1038/nm0797-730 · Cited by 5,864
Döhner, H., Estey, E., Grimwade, D., Amadori, S., Appelbaum, F. R., Büchner, T., Dombret, H., Ebert, B. L., Fenaux, P., Larson, R. A., et al. (2017) · Blood · doi:10.1182/blood-2016-08-733196 · Cited by 5,775
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
The Cancer Genome Atlas Research Network (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1301689 · Cited by 5,078
Simultaneous epitope and transcriptome measurement in single cells
Stoeckius, M., Hafemeister, C., Stephenson, W., Houck-Loomis, B., Chattopadhyay, P. K., Swerdlow, H., Satija, R., & Smibert, P. (2017) · Nature Methods · doi:10.1038/nmeth.4380 · Cited by 3,098
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
Souers, A. J., Leverson, J. D., Boghaert, E. R., Ackler, S. L., Catron, N. D., Chen, J., Dayton, B. D., Ding, H., Enschede, S. H., Fairbrother, W. J., et al. (2013) · Nature Medicine · doi:10.1038/nm.3048 · Cited by 3,058
Fenaux, P., Mufti, G. J., Hellstrom-Lindberg, E., Santini, V., Finelli, C., Giagounidis, A., Schoch, R., Gattermann, N., Sanz, G., List, A., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70003-8 · Cited by 2,663 · cited 1×
“However, response to HMA therapy is limited and long-term overall survival is negligible (4,5).”
BackgroundDiNardo, C. D., Pratz, K., Pullarkat, V., Jonas, B. A., Arellano, M., Becker, P. S., Frankfurt, O., Konopleva, M., Wei, A. H., Kantarjian, H. M., et al. (2019) · Blood · doi:10.1182/blood-2018-08-868752 · Cited by 1,825
Self-citationKantarjian, H., Issa, J. J., Rosenfeld, C. S., Bennett, J. M., Albitar, M., DiPersio, J., Klimek, V., Slack, J., de Castro, C., Ravandi, F., et al. (2006) · Cancer · doi:10.1002/cncr.21792 · Cited by 1,530
Transformation from committed progenitor to leukaemia stem cell initiated by MLL–AF9
Krivtsov, A. V., Twomey, D., Feng, Z., Stubbs, M. C., Wang, Y., Faber, J., Levine, J. E., Wang, J., Hahn, W. C., Gilliland, D. G., et al. (2006) · Nature · doi:10.1038/nature04980 · Cited by 1,513 · cited 1×
“This is notable because unlike most other previously reported LSC signatures, MLL-specific LSCs have a myeloid phenotype (39,40).”
ResultLagadinou, E. D., Sach, A., Callahan, K., Rossi, R. M., Neering, S. J., Minhajuddin, M., Ashton, J. M., Pei, S., Grose, V., O’Dwyer, K. M., et al. (2013) · Cell Stem Cell · doi:10.1016/j.stem.2012.12.013 · Cited by 1,399
Self-citationFunctional genomic landscape of acute myeloid leukaemia
Tyner, J. W., Tognon, C. E., Bottomly, D., Wilmot, B., Kurtz, S. E., Savage, S. L., Long, N., Schultz, A. R., Traer, E., Abel, M., et al. (2018) · Nature · doi:10.1038/s41586-018-0623-z · Cited by 1,303
Self-citationOncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function
Viale, A., Pettazzoni, P., Lyssiotis, C. A., Ying, H., Sánchez, N., Marchesini, M., Carugo, A., Green, T., Seth, S., Giuliani, V., et al. (2014) · Nature · doi:10.1038/nature13611 · Cited by 1,259
Single-Cell RNA-Seq Reveals AML Hierarchies Relevant to Disease Progression and Immunity
van Galen, P., Hovestadt, V., Wadsworth II, M. H., Hughes, T. K., Griffin, G. K., Battaglia, S., Verga, J. A., Stephansky, J., Pastika, T. J., Lombardi Story, J., et al. (2019) · Cell · doi:10.1016/j.cell.2019.01.031 · Cited by 1,164
Stem cell gene expression programs influence clinical outcome in human leukemia
Eppert, K., Takenaka, K., Lechman, E. R., Waldron, L., Nilsson, B., van Galen, P., Metzeler, K. H., Poeppl, A., Ling, V., Beyene, J., et al. (2011) · Nature Medicine · doi:10.1038/nm.2415 · Cited by 1,041
Densely Interconnected Transcriptional Circuits Control Cell States in Human Hematopoiesis
Novershtern, N., Subramanian, A., Lawton, L. N., Mak, R. H., Haining, W. N., McConkey, M. E., Habib, N., Yosef, N., Chang, C. Y., Shay, T., et al. (2011) · Cell · doi:10.1016/j.cell.2011.01.004 · Cited by 942
A 17-gene stemness score for rapid determination of risk in acute leukaemia
Ng, S. W. K., Mitchell, A., Kennedy, J. A., Chen, W. C., McLeod, J., Ibrahimova, N., Arruda, A., Popescu, A., Gupta, V., Schimmer, A. D., et al. (2016) · Nature · doi:10.1038/nature20598 · Cited by 912
Pollyea, D. A., Stevens, B. M., Jones, C. L., Winters, A., Pei, S., Minhajuddin, M., D’Alessandro, A., Culp-Hill, R., Riemondy, K. A., Gillen, A. E., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0233-1 · Cited by 778 · cited 3×
“Our results showed VEN+AZA effectively impaired the LSC engraftment potential in primitive AML as expected (10), but less so in monocytic AML (Fig.”
BackgroundResultInfluentialSelf-citationChromatin state dynamics during blood formation
Lara-Astiaso, D., Weiner, A., Lorenzo-Vivas, E., Zaretsky, I., Jaitin, D. A., David, E., Keren-Shaul, H., Mildner, A., Winter, D., Jung, S., et al. (2014) · Science · doi:10.1126/science.1256271 · Cited by 776
Selective BCL-2 Inhibition by ABT-199 Causes On-Target Cell Death in Acute Myeloid Leukemia
Pan, R., Hogdal, L. J., Benito, J. M., Bucci, D., Han, L., Borthakur, G., Cortes, J., DeAngelo, D. J., Debose, L., Mu, H., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0609 · Cited by 735
DiNardo, C. D., Pratz, K. W., Letai, A., Jonas, B. A., Wei, A. H., Thirman, M., Arellano, M., Frattini, M. G., Kantarjian, H., Popovic, R., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30010-x · Cited by 722
Self-citationInhibition of Mitochondrial Translation as a Therapeutic Strategy for Human Acute Myeloid Leukemia
Škrtić, M., Sriskanthadevan, S., Jhas, B., Gebbia, M., Wang, X., Wang, Z., Hurren, R., Jitkova, Y., Gronda, M., Maclean, N., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.10.015 · Cited by 678
Roesch, A., Vultur, A., Bogeski, I., Wang, H., Zimmermann, K. M., Speicher, D., Körbel, C., Laschke, M. W., Gimotty, P. A., Philipp, S. E., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.05.003 · Cited by 670
Tracing the origins of relapse in acute myeloid leukaemia to stem cells
Shlush, L. I., Mitchell, A., Heisler, L., Abelson, S., Ng, S. W. K., Trotman-Grant, A., Medeiros, J. J. F., Rao-Bhatia, A., Jaciw-Zurakowsky, I., Marke, R., et al. (2017) · Nature · doi:10.1038/nature22993 · Cited by 595
Inhibition of Amino Acid Metabolism Selectively Targets Human Leukemia Stem Cells
Jones, C. L., Stevens, B. M., D'Alessandro, A., Reisz, J. A., Culp-Hill, R., Nemkov, T., Pei, S., Khan, N., Adane, B., Ye, H., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.10.005 · Cited by 585
Self-citationCD14: Cell surface receptor and differentiation marker
Ziegler-Heitbrock, H. W. L., & Ulevitch, R. J. (1993) · Immunology Today · doi:10.1016/0167-5699(93)90212-4 · Cited by 584
Metabolic state of glioma stem cells and nontumorigenic cells
Vlashi, E., Lagadec, C., Vergnes, L., Matsutani, T., Masui, K., Poulou, M., Popescu, R., Della Donna, L., Evers, P., Dekmezian, C., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1106704108 · Cited by 553
Ramsey, H. E., Fischer, M. A., Lee, T., Gorska, A. E., Arrate, M. P., Fuller, L., Boyd, K. L., Strickland, S. A., Sensintaffar, J., Hogdal, L. J., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0140 · Cited by 379
Self-citationThe TP53 Apoptotic Network Is a Primary Mediator of Resistance to BCL2 Inhibition in AML Cells
Nechiporuk, T., Kurtz, S. E., Nikolova, O., Liu, T., Jones, C. L., D'Alessandro, A., Culp-Hill, R., d'Almeida, A., Joshi, S. K., Rosenberg, M., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0125 · Cited by 378
Self-citationSomervaille, T. C. P., Matheny, C. J., Spencer, G. J., Iwasaki, M., Rinn, J. L., Witten, D. M., Chang, H. Y., Shurtleff, S. A., Downing, J. R., & Cleary, M. L. (2009) · Cell Stem Cell · doi:10.1016/j.stem.2008.11.015 · Cited by 357
Cole, A., Wang, Z., Coyaud, E., Voisin, V., Gronda, M., Jitkova, Y., Mattson, R., Hurren, R., Babovic, S., Maclean, N., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.05.004 · Cited by 352
Anti-apoptotic BCL-2 family members in development
Opferman, J. T., & Kothari, A. (2018) · Cell Death & Differentiation · doi:10.1038/cdd.2017.170 · Cited by 347
Büchner, T., Berdel, W. E., Haferlach, C., Haferlach, T., Schnittger, S., Müller-Tidow, C., Braess, J., Spiekermann, K., Kienast, J., Staib, P., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.4245 · Cited by 338
Sriskanthadevan, S., Jeyaraju, D. V., Chung, T. E., Prabha, S., Xu, W., Skrtic, M., Jhas, B., Hurren, R., Gronda, M., Wang, X., et al. (2015) · Blood · doi:10.1182/blood-2014-08-594408 · Cited by 329
MafB is an inducer of monocytic differentiation
Kelly, L. M. (2000) · The EMBO Journal · doi:10.1093/emboj/19.9.1987 · Cited by 305
AMPK/FIS1-Mediated Mitophagy Is Required for Self-Renewal of Human AML Stem Cells
Pei, S., Minhajuddin, M., Adane, B., Khan, N., Stevens, B. M., Mack, S. C., Lai, S., Rich, J. N., Inguva, A., Shannon, K. M., et al. (2018) · Cell Stem Cell · doi:10.1016/j.stem.2018.05.021 · Cited by 301
Self-citationTherapeutic targeting of acute myeloid leukemia stem cells
Pollyea, D. A., & Jordan, C. T. (2017) · Blood · doi:10.1182/blood-2016-10-696039 · Cited by 299
Self-citationEvolution of acute myelogenous leukemia stem cell properties after treatment and progression
Ho, T.-C., LaMere, M., Stevens, B. M., Ashton, J. M., Myers, J. R., O’Dwyer, K. M., Liesveld, J. L., Mendler, J. H., Guzman, M., Morrissette, J. D., et al. (2016) · Blood · doi:10.1182/blood-2016-02-695312 · Cited by 232
Self-citationKuusanmäki, H., Leppä, A.-M., Pölönen, P., Kontro, M., Dufva, O., Deb, D., Yadav, B., Brück, O., Kumar, A., Everaus, H., et al. (2020) · Haematologica · doi:10.3324/haematol.2018.214882 · Cited by 186 · cited 1×
“In addition, recent in vitro studies show reduced venetoclax sensitivity in primary AML cells with a monocytic phenotype(13).”
BackgroundCarrington, E. M., Zhan, Y., Brady, J. L., Zhang, J., Sutherland, R. M., Anstee, N. S., Schenk, R. L., Vikstrom, I. B., Delconte, R. B., Segal, D., et al. (2017) · Cell Death and Differentiation · doi:10.1038/cdd.2017.30 · Cited by 182
Nemkov, T., D’Alessandro, A., & Hansen, K. C. (2015) · Amino Acids · doi:10.1007/s00726-015-2019-9 · Cited by 163
Self-citationLysosomal disruption preferentially targets acute myeloid leukemia cells and progenitors
Sukhai, M. A., Prabha, S., Hurren, R., Rutledge, A. C., Lee, A. Y., Sriskanthadevan, S., Sun, H., Wang, X., Škrtić, M., Seneviratne, A. K., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci64180 · Cited by 162
Acute myeloid leukaemia in the elderly: a review
Pollyea, D. A., Kohrt, H. E. K., & Medeiros, B. C. (2011) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08470.x · Cited by 150
Self-citationAcute myeloid leukemia in the older adults
Almeida, A. M., & Ramos, F. (2016) · Leukemia Research Reports · doi:10.1016/j.lrr.2016.06.001 · Cited by 147
Hintzsche, J. D., Kim, J., Yadav, V. K., Amato, C. M., Robinson, S. E., Seelenfreund, E., Shellman, Y. G., Wisell, J. A., Applegate, A. J., McCarter, M. D., et al. (2016) · Journal of the American Medical Informatics Association · doi:10.1093/jamia/ocw022 · Cited by 47
Self-citationNoto, R. D., Pardo, C. L., Schiavone, E. M., Manzo, C., Vacca, C., Ferrara, F., & Vecchio, L. D. (1996) · British Journal of Haematology · doi:10.1046/j.1365-2141.1996.395932.x · Cited by 45
Immunophenotypic identification of acute myeloid leukemia with monocytic differentiation
Xu, Y., McKenna, R. W., Wilson, K. S., Karandikar, N. J., Schultz, R. A., & Kroft, S. H. (2006) · Leukemia · doi:10.1038/sj.leu.2404242 · Cited by 35
Garcia, C., Gardner, D., & Reichard, K. K. (2008) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0b013e31815db477 · Cited by 24
Differences in the prevalence of PTPN11 mutations in FAB M5 paediatric acute myeloid leukaemia
Goemans, B. F., Zwaan, C. M., Martinelli, S., Harrell, P. M., de Lange, Carta, C., Reinhardt, D., Hählen, K., Creutzig, U., Tartaglia, M., et al. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05685.x · Cited by 22
Cited by
The BCL2 family: from apoptosis mechanisms to new advances in targeted therapy
Vogler, M., Braun, Y., Smith, V. M., Westhoff, M.-A., Pereira, R. S., Pieper, N. M., Anders, M., Callens, M., Vervliet, T., Abbas, M., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02176-0 · Cited by 462
Acute myeloid leukemia: 2023 update on diagnosis, risk‐stratification, and management
Shimony, S., Stahl, M., & Stone, R. M. (2023) · American Journal of Hematology · doi:10.1002/ajh.26822 · Cited by 448
Integrative Analysis of Drug Response and Clinical Outcome in Acute Myeloid Leukemia
Bottomly, D., Long, N., Schultz, A. R., Kurtz, S. E., Tognon, C. E., Johnson, K., Abel, M., Agarwal, A., Avaylon, S., Benton, E., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.07.002 · Cited by 403
Self-citationZeng, A. G. X., Bansal, S., Jin, L., Mitchell, A., Chen, W. C., Abbas, H. A., Chan-Seng-Yue, M., Voisin, V., van Galen, P., Tierens, A., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01819-x · Cited by 332
DiNardo, C. D., Maiti, A., Rausch, C. R., Pemmaraju, N., Naqvi, K., Daver, N. G., Kadia, T. M., Borthakur, G., Ohanian, M., Alvarado, Y., et al. (2020) · The Lancet Haematology · doi:10.1016/s2352-3026(20)30210-6 · Cited by 324
Metadata
- Authors
- Pei, S., Pollyea, D. A., Gustafson, A., Stevens, B. M., Minhajuddin, M., Fu, R., Riemondy, K. A., Gillen, A. E., Sheridan, R. M., Kim, J., Costello, J. C., Amaya, M. L., Inguva, A., Winters, A., Ye, H., Krug, A., Jones, C. L., Adane, B., Khan, N., Ponder, J., Schowinsky, J., Abbott, D., Hammes, A., Myers, J. R., Ashton, J. M., Nemkov, T., D'Alessandro, A., Gutman, J. A., Ramsey, H. E., Savona, M. R., Smith, C. A., & Jordan, C. T.
- Venue
- Cancer Discovery
- Published
- 2020-04-01
- Volume
- 10
- Issue
- 4
- Pages
- 536-551
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W3001120382
- Cited by
- 562
- References
- 48
- FWCI
- 34.43
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.